



## Amplix at a Glance

- Developing treatments for life-threatening invasive fungal infections
- Phase 1 studies in healthy volunteers completed
- Highly experienced management team and board of directors
- \$118.5 million in venture capital and \$10 million in NIH grants
- Lead investors: RiverVest Venture Partners, NEA, BioMed Ventures, 3x5 RiverVest II, Sofinnova Venture Partners, Lundbeckfonden Ventures, Arix Bioscience, and Pappas Capital
- Located in San Diego, California

Amplix Pharmaceuticals is developing a new class of antifungal medicine to overcome the limitations of existing therapeutic options. Amplix is developing APX001, a broad-spectrum antifungal drug with a novel mechanism of action for the treatment of life-threatening, invasive fungal infections caused by *Candida*, *Aspergillus* and by rare, hard-to-treat molds, including strains that are resistant to existing treatments. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 studies currently underway.

Amplix's leadership team has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare (orphan) conditions. The company is privately held and has received over \$10 million in NIH grants and raised a total of \$118.5 million in venture capital funding. Key investors include RiverVest Venture Partners, NEA, BioMed Ventures, 3x5 RiverVest II, Sofinnova Venture Partners, Lundbeckfonden Ventures, Arix Bioscience, and Pappas Capital.

## Product Description: APX001

APX001 is the prodrug of APX001A, which is a first-in-class small molecule drug candidate that inhibits the conserved fungal enzyme Gwt1, compromising growth of major fungal pathogens, including *Candida* and *Aspergillus*. APX001A has been evaluated extensively in preclinical studies, demonstrating broad-spectrum activity against common species of *Candida* spp., and *Aspergillus* spp., including multidrug-resistant strains, and rare, difficult-to-treat molds including *Fusarium* spp., *Scedosporium* spp., and fungi from the Mucorales order.

There are over 600,000 cases of invasive fungal infections due to *Candida* spp., *Aspergillus* spp., and rare molds annually worldwide. Patients with compromised immune systems due to chemotherapy or other immune-compromising medical treatments are susceptible to these potentially deadly fungal infections.

Amplix is developing once-daily intravenous (IV) and oral formulations of APX001 to address the need for hospital use, as well as continued therapy after hospital discharge.

## Management Team

**Ciara Kennedy, Ph.D.**

President and CEO

**Michael Hodges, M.D.**

Chief Medical Officer

**Karen Joy Shaw, Ph.D.**

Chief Scientific Officer

**Alan Fuhrman**

Chief Financial Officer

## Board of Directors

**Mike Grey**

Executive Chairman

**Paul C. Grint, M.D.**

President and CEO,  
Regulus Therapeutics

**Elaine J. Heron, Ph.D.**

Board of Directors, BioMarin

**Ed Mathers**

Partner, NEA

**Niall O'Donnell, Ph.D.**

Managing Director, RiverVest

**Ciara Kennedy, Ph.D.**

President and CEO

**Anand Mehra, M.D.**

Managing Partner,  
Sofinnova Ventures

**Johan Kördel, Ph.D.**

Senior Partner,  
Lundbeckfonden Ventures

## Contact

info@amplix.com

(858) 345-1755